Valuation as at 2026-08-04 · refreshed with the S&P 500 Most Undervalued screen
About Eli Lilly and Company
Eli Lilly and Company discovers, develops, manufactures, and markets human pharmaceutical products in the United States, Europe, China, Japan, and internationally. The company offers cardiometabolic health products, including Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, such as Cyramza for the second-line treatment of gastric cancer or gastro-esophageal junction adenocarcinoma; Erbitux for colorectal cancers and head and neck cancers; Inluriyo for breast cancer; Jaypirca for chronic lymphocytic leukemia or small lymphocytic lymphoma; Retevmo for the treatment of metastatic NSCLC; TYVYT for classic hodgkin's lymphoma; and Verzenio for breast cancer.
Source: Yahoo Finance company profile · factual description, not KashVector commentary
Eli Lilly and Company LLY
Healthcare · Drug Manufacturers - General
LLY's price & financial trends
Quarterly reporting periods — the most granular consistent series Yahoo provides for this market.
Data refreshed 2026-08-04
Share price · last 2 years
Earnings per share (diluted)
Free cash flow
Dividend per share
Intrinsic value estimate · 5-year forecast
Assumptions used in this valuation
Every input below is either fetched live from Yahoo Finance or a documented default — nothing is hidden.
| Bear | Base | Bull | |
|---|---|---|---|
| 5-yr FCF growth | 12.5% | 25.0% | 30.0% |
| Terminal growth | 2.5% | 2.5% | 2.5% |
| WACC (discount rate) | 8.37% | 7.37% | 6.37% |
Cost of Equity = Risk-free rate + Beta × Equity Risk Premium = 4.75% + 0.51 × 5.50% = 7.53% · WACC = weighted by 96%/4% capital structure
These numbers come from running Eli Lilly and Company's cash flows through the mechanical DCF formula and assumptions above — not from any view on the news, management, or LLY's competitive position. What is DCF?
Want to test your own growth or discount-rate assumptions?Open the full interactive calculator, pre-filled with LLY →
More S&P 500 Most Undervalued stocks
Not financial advice. DCF valuations are highly sensitive to assumptions — small changes in growth rate or discount rate produce large swings in output. This is a mechanical calculation, not a recommendation to buy, hold, or sell.
About this valuation
Refreshed on the same cycle as the S&P 500 Most Undervalued screen. Change any assumption yourself in the full interactive tool.
Frequently asked questions
Is LLY undervalued?
The Base-case DCF estimates intrinsic value at $502.26 vs a current price of $1,121.36 — a -55.2% margin, so the Base case reads overvalued. This is a mechanical output, not advice.